Page last updated: 2024-11-07

medica 16

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

MEDICA 16 : An alpha,omega-dicarboxylic acid that is hexadecanedioic acid carrying methyl groups at positions 3 and 14. It is a free fatty acid 1 (FFA1/GPR40) receptor agonist and an ATP citrate lyase inhibitor, and exhibits hypolipidemic and antidiabetogenic properties. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID121871
CHEMBL ID63829
CHEBI ID149582
SCHEMBL ID186164
MeSH IDM0157644

Synonyms (34)

Synonym
gtpl1053
medica 16, powder, >=97% (hplc)
NCGC00165834-01
medica 16
medic-16
3,3,14,14-tetramethylhexanedecanedioic acid
hexadecandioic acid, 3,3,14,14-tetramethyl-
CHEMBL63829 ,
3,3,14,14-tetramethyl-hexadecanedioic acid
beta,beta'-tetramethylhexadecanedioic acid
beta,beta'-tetramethylhexadecane-alpha,omega-dioic acid
CHEBI:149582
medica-16
3,3,14,14-tetramethylhexadecanedioic acid
medica16
87272-20-6
bdbm50018569
tc257flpck ,
unii-tc257flpck
SCHEMBL186164
3,3,14,14-tetramethyl-hexadecane-1,16-dioic acid
HYSMCRNFENOHJH-UHFFFAOYSA-N
HB0877
AKOS024458254
c20h38o4
HMS3649J11
DTXSID00236246
hexadecanedioic acid, 3,3,14,14-tetramethyl-
Q27084045
sr-01000946665
SR-01000946665-1
CS-0027968
HY-P1123
MS-25251

Research Excerpts

Treatment

ExcerptReferenceRelevance
"MEDICA 16 treatment resulted in an insulin-induced decrease in hepatic glucose production, together with an insulin-induced increase in total-body glucose disposal."( Sensitization to insulin induced by beta,beta'-methyl-substituted hexadecanedioic acid (MEDICA 16) in obese Zucker rats in vivo.
Bar-Tana, J; Itach, E; Kalderon, B; Mayorek, N, 1997
)
1.24
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antilipemic drugA substance used to treat hyperlipidemia (an excess of lipids in the blood).
EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitorAn EC 6.4.1.* (C-C bond-forming ligase) inhibitor that interferes with the action of acetyl-CoA carboxylase (EC 6.4.1.2).
EC 2.3.3.8 (ATP citrate synthase) inhibitorAn EC 2.3.3.* (acyltransferase converting acyl to alkyl group on transfer) inhibitor that interferes with the action of ATP citrate synthase (EC 2.3.3.8).
G-protein-coupled receptor agonistAn agonist that binds to and activates G-protein-coupled receptors
hypoglycemic agentA drug which lowers the blood glucose level.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
alpha,omega-dicarboxylic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency63.09570.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency17.74070.140911.194039.8107AID2451
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency35.48130.354828.065989.1251AID504847
DNA polymerase kappa isoform 1Homo sapiens (human)Potency37.68580.031622.3146100.0000AID588579
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-citrate synthase Rattus norvegicus (Norway rat)Ki11.66670.15004.75718.0000AID1408667; AID697030; AID697049
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID171966Hypolipidemic activity in rats by evaluating the plasma cholesterol level at a dose of 10 mg/kg for seven days1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids.
AID171970Hypolipidemic activity in rats by evaluating the plasma triacylglycerol level at a dose of 10 mg/kg for seven days1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids.
AID190208Percent of hypolipidemic activity in rats by evaluating the plasma cholesterol level at 0.1%(w/w) in diet for three days1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids.
AID181356Inhibition of lipid synthesis, by incorporation of 3H20 into 3-beta-hydroxysterols in cultured rat hepatocytes1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids.
AID185231Percent inhibition of lipid synthesis by incorporation of 3H20 into saponified fatty acids in rat1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids.
AID155970Liver peroxisomal enoyl-CoA hydratase activity in rats1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids.
AID190209Percent of hypolipidemic activity in rats by evaluating the plasma triacylglycerol level at 0.1%(w/w) in diet for three days1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids.
AID697030Competitive inhibition of rat liver ACLY using CoA as substrate by spectrophotometric analysis2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
The lipogenesis pathway as a cancer target.
AID32399Inhibition against ATP-citrate lyase in liver.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids.
AID155971Percent of liver peroxisomal enoyl-CoA hydratase activity in rats1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids.
AID184402Percent Inhibition of lipid synthesis, by incorporation of 3H20 into 3-beta-hydroxysterols in rat1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids.
AID181359Inhibition of lipid synthesis, by incorporation of 3H20 into saponified fatty acids in cultured rat hepatocytes1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids.
AID697043Inhibition of rat liver ACC2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
The lipogenesis pathway as a cancer target.
AID697049Competitive inhibition of rat liver ACLY using citrate as substrate by spectrophotometric analysis2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
The lipogenesis pathway as a cancer target.
AID182913In vivo percent inhibition of lipid synthesis, by incorporation of 3H20 into liver saponified fatty acids in rat, at 0.1%(w/w) in diet for three days1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids.
AID181357Inhibition of lipid synthesis, by incorporation of 3H20 into 3-beta-hydroxysterols in rat1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids.
AID181361Inhibition of lipid synthesis, by incorporation of 3H20 into total liver lipids in rat1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids.
AID181360Inhibition of lipid synthesis, by incorporation of 3H20 into saponified fatty acids in rat1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids.
AID1408667Inhibition of rat liver ACLY2018European journal of medicinal chemistry, Sep-05, Volume: 157ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.
AID182912In vivo percent inhibition of lipid synthesis by incorporation of 3H20 into 3-beta-hydroxysterols in rat, at 0.1%(w/w) in diet for three days1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids.
AID1345809Human FFA1 receptor (Free fatty acid receptors)2003Biochemical and biophysical research communications, Feb-07, Volume: 301, Issue:2
A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (20.59)18.7374
1990's14 (41.18)18.2507
2000's9 (26.47)29.6817
2010's4 (11.76)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.24 (24.57)
Research Supply Index3.58 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.71%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (94.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]